The size of the Liver Cancer Therapeutics Market in North America was worth USD 243.91 million in 2021 and estimated to be growing at a CAGR of 8.56%, to reach USD 367.78 million by 2026.
North America has the largest market share for lung cancer diagnostics and therapeutics market. This is due to technological innovations in cancer treatment devices.
With advancement in technology, novel drugs are being developed which work in a different way from usual chemotherapy drugs, by targeting precise parts of cancer cells or their neighbouring environment. Treating cancer is still not easy because disease symptoms generally appear in the late stage of the disease, resulting in a low diagnosis rate that in turn disturbs the patient volume available for treatment.
Technological developments, for instance non-invasive radiation therapy and rising incidence of cancer are key drivers for the North America lung cancer therapeutic market. Moreover, increasing government support and funding for research and development field has promoted the market growth.
On the other hand, high costs associated with research activities and the expiry of copyrights of some bestseller drugs are obstructing the growth of the market.
This research report on the North America Liver Cancer Therapeutics Market has been segmented and sub-segmented into the following categories
By Type:
By Therapeutics:
By End Users:
By Country:
On the basis of therapeutics, the Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.
Regionally, the United States leads the North America region market due to high number of cancer cases in US which is augmenting the liver cancer therapeutics market for the country.
Companies playing a dominant role in the North America Liver Cancer Therapeutics Market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Primary
5.1.2 Secondary
5.1.3 Benign Liver growths
5.2 By Therapeutics
5.2.1 Hepatocellular Carcinoma
5.2.2 Cholangio carcinoma
5.2.3 Hepatoblastoma
5.2.4 Targeted Therapy
5.3 By End-Users
5.3.1 Pediatrics
5.3.2 Adults
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Alnylam Pharmaceuticals Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 ImClone Systems Inc.
9.3 Onyx Pharmaceuticals Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Pfizer Inc.
9.6 ArQule Inc.
9.7 Jennerex Biotherapeutics Inc.
9.8 Celsion Corp.
9.9 Bayer Schering Pharma AG
9.10 4SC AG
9.11 Bristol-Myers Squibb Company
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
